Ushercell HIV prevention study starts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Polydex/Conrad's Ushercell (cellulose sulfate) Phase III studies will test the microbicidal gel's efficacy in prevention of HIV and other sexually transmitted infections. The first HIV prevention study, cleared by FDA in summer 2004, is underway in Nigeria. "A second study's protocol has just been approved by the FDA and will be conducted by Conrad in several countries with a high incidence of HIV infection," Polydex says. Both placebo-controlled studies are enrolling HIV negative women who are at high-risk of contracting HIV through vaginal intercourse. Contraceptive studies of cellulose sulfate are ongoing...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.